Véronique Harrivel

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé et al. · Blood Advances · 2019 · 121 citations · Full text

Medicine, Hematology, Oncology +17

Concordance of assays designed for the quantification of JAK2V617F: a multicenter study

Éric Lippert, François Girodon, E. Hammond et al. · Haematologica · 2008 · 77 citations · Full text

Life Sciences, Genetics, Molecular Biology +17

Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis

Florian Renosi, Anne Roggy, Ambre Giguelay et al. · Blood Advances · 2021 · 55 citations · Full text

Medicine, Cancer Biology, Oncology +17

5‐Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy

S. S. Ivanoff, Bérengère Gruson, Sylvain Chantepie et al. · American Journal of Hematology · 2013 · 49 citations · Full text

Medicine, Hematology, Oncology +14

Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics

Delphine Lebon, François Vergez, Sarah Bertoli et al. · Leukemia Research · 2015 · 36 citations

Life Sciences, Hematology, Oncology +11